COMPANY

Fimbrion Therapeutics

HQ: St. Louis, MO source · fimbrion.com ↗ · Midwest

Location: St. Louis, MO · source · Oct 15, 2026

Profile checked Oct 10, 2026

13NIH grants

Funding and NIH signals

NIH award NIH awarded $300K (SBIR Phase I 5R43AI192175-02, continuation, notice Sep 3, 2026); 3 NIH awards totaling $900K in the last 12 months. NIH RePORTER 5R43AI192175-02 (Sep 3, 2026)
Evidence (3 events)
- Sep 3, 2026 · NIH RePORTER 5R43AI192175-02
  Organization: FIMBRION THERAPEUTICS, INC.; City/State: SAINT LOUIS, MO; Project number: 5R43AI192175-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-09-03; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Thiazolino-Pyridone Compounds as Novel Antimycobacterial Drugs for Tuberculosis; Organization type: Domestic For-Profits
- Aug 6, 2026 · NIH RePORTER 5R43AI192169-02
  Organization: FIMBRION THERAPEUTICS, INC.; City/State: SAINT LOUIS, MO; Project number: 5R43AI192169-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-08-06; FY total cost (award amount): 300000; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Small Molecule Glycoside Inhibitors of LecB for the Treatment of Pseudomonas Infections; Organization type: Domestic For-Profits
- Jul 29, 2026 · NIH RePORTER 5R43AI188991-02
  Organization: FIMBRION THERAPEUTICS, INC.; City/State: SAINT LOUIS, MO; Project number: 5R43AI188991-02; Activity code: R43; Fiscal year: 2026; Award notice date: 2026-07-29; FY total cost (award amount): 300001; Administering IC: National Institute of Allergy and Infectious Diseases; Project title: Heterocyclic Inhibitors of QcrB as Novel Drugs for Infections Caused by Nontuberculous Mycobacteria; Organization type: Domestic For-Profits

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

Sep 3, 2026 Grant Government grant — SBIR: $300,000 (annual award, as published), announced Sep 3, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 6, 2026 Grant Government grant — SBIR: $300,000 (annual award, as published), announced Aug 6, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 29, 2026 Grant Government grant — SBIR: $300,001 (annual award, as published), announced Jul 29, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Sep 9, 2025 Grant Government grant — SBIR: $300,000 (annual award, as published), announced Sep 9, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 15, 2025 Grant Government grant — SBIR: $300,000 (annual award, as published), announced Aug 15, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 23, 2025 Grant Government grant — SBIR: $300,001 (annual award, as published), announced Jul 23, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

Funding

Last 2 years.

Sep 3, 2026 Government grant — SBIR: $300,000 (annual award, as published), announced Sep 3, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 6, 2026 Government grant — SBIR: $300,000 (annual award, as published), announced Aug 6, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 29, 2026 Government grant — SBIR: $300,001 (annual award, as published), announced Jul 29, 2026. Agency: NIH/NIAID. Source: government award database. source ↗
Sep 9, 2025 Government grant — SBIR: $300,000 (annual award, as published), announced Sep 9, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Aug 15, 2025 Government grant — SBIR: $300,000 (annual award, as published), announced Aug 15, 2025. Agency: NIH/NIAID. Source: government award database. source ↗
Jul 23, 2025 Government grant — SBIR: $300,001 (annual award, as published), announced Jul 23, 2025. Agency: NIH/NIAID. Source: government award database. source ↗

NIH awards 13

Annual award amounts. Total $7.0M.

Jan 31, 2024 NIH award 5R43AI172559-02 FY2024: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Thiazolino-Pyridone Compound source ↗
Jan 24, 2024 NIH award 5R43AI174482-02 FY2024: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI MCGRANE, LAUREL; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. FimH-Targeting Antibody-Recruiting source ↗
Dec 7, 2023 NIH award 5R44AI149833-05 FY2024: $994,977 awarded for that fiscal year; activity R44 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Heterocyclic Inhibitors of Q source ↗
Mar 8, 2023 NIH award 1R43AI172559-01A1 FY2023: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Thiazolino-Pyridone Compou source ↗
Feb 28, 2023 NIH award 1R43AI174482-01 FY2023: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI MCGRANE, LAUREL; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. FimH-Targeting Antibody-Recruiting source ↗
Nov 7, 2022 NIH award 5R44AI149833-04 FY2023: $997,875 awarded for that fiscal year; activity R44 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Heterocyclic Inhibitors of Q source ↗
Dec 8, 2021 NIH award 2R44AI149833-03 FY2022: $1,000,000 awarded for that fiscal year; activity R44 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Heterocyclic Inhibitors of source ↗
Nov 30, 2020 NIH award 5R43AI149833-02 FY2021: $293,050 awarded for that fiscal year; activity R43 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Heterocyclic Inhibitors of Q source ↗
Dec 13, 2019 NIH award 1R43AI149833-01 FY2020: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Heterocyclic Inhibitors of Q source ↗
Feb 7, 2018 NIH award 5R44AI106112-04 FY2018: $724,797 awarded for that fiscal year; activity R44 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Anti-Virulence FimH Inhibito source ↗
Mar 10, 2017 NIH award 2R44AI106112-03 FY2017: $901,235 awarded for that fiscal year; activity R44 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Anti-Virulence FimH Inhibito source ↗
Jun 16, 2015 NIH award 5R43AI106112-02 FY2015: $269,019 awarded for that fiscal year; activity R43 (SBIR); PI HANNAN, THOMAS JOSEPH; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Anti-virulence FimH inhibito source ↗
Jul 18, 2014 NIH award 1R43AI106112-01A1 FY2014: $300,000 awarded for that fiscal year; activity R43 (SBIR); PI CUSUMANO, ZACHARY; recipient as written: FIMBRION THERAPEUTICS, INC., SAINT LOUIS, MO. Anti-virulence FimH inhibitors source ↗